Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2024-07-25 Earnings Release
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
Earnings Release Classification · 1% confidence The document is explicitly titled "Press release" and announces "financial results for the first half of 2024." It provides key financial highlights (Total-sales growth, Core operating margin), upgraded full-year guidance, and detailed tables summarizing H1 2024 and H1 2023 consolidated results. This content structure—a summary announcement of period results, including key metrics and forward guidance—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the detailed Interim/Quarterly Report (IR), as it is presented as a high-level press release summarizing the period, often preceding the full regulatory filing or detailed management discussion. H1 2024
2024-07-25 English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 29 - 2024
Director's Dealing Classification · 1% confidence The document text consists of detailed tables reporting daily transactions of shares ('Volume total journalier', 'Prix pondéré moyen journalier d'acquisition') and specific transaction details including 'Jour/heure de la Transaction', 'Quantité achetée', and 'Objectif du rachat' (which mentions 'MAR Regulation Art 5 §2'). This structure is characteristic of mandatory regulatory filings disclosing personal share transactions by directors or executives, or transactions related to share buybacks/issues by the company itself. The presence of 'Nom du PSI' (Participant Intervenant sur le Système) and transaction references strongly suggests insider or principal trading disclosure. Comparing this to the definitions, 'Director's Dealing' (DIRS) covers personal trades by directors, and 'Transaction in Own Shares' (POS) covers company buybacks. Since the second table explicitly mentions 'Objectif du rachat' (Buyback objective) and details transactions executed by an intermediary ('Natixis') on behalf of the issuer (IPSEN), this strongly points towards a report of the company transacting in its own shares (share repurchase program). Therefore, the classification is POS.
2024-07-23 French
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024
Transaction in Own Shares Classification · 1% confidence The document text consists of detailed tables reporting daily transactions involving the issuer's shares, including transaction dates, volumes, prices, and broker information. Crucially, the tables contain columns like 'Purpose of the buyback' and explicitly mention 'MAR Regulation Art 5 §2'. This structure is characteristic of mandatory regulatory filings detailing insider transactions or share buybacks/transactions by directors or the company itself. Comparing this content to the definitions, the category 'Director's Dealing (Code: DIRS)' covers reports of personal share transactions by directors, and 'Transaction in Own Shares (Code: POS)' covers the company buying back shares. Since the document details multiple transactions by a broker (Natixis) on behalf of the issuer, and explicitly mentions the purpose as 'MAR Regulation Art 5 §2' (which relates to market abuse regulation concerning transactions), it strongly indicates a report of share transactions. Given the context of detailed transaction logs, 'Transaction in Own Shares (POS)' is the most precise fit if the transactions are buybacks/sales by the company, or 'DIRS' if they were director trades. The presence of 'Purpose of the buyback' suggests this is a report of the company executing a buyback program. Therefore, POS is the best fit.
2024-07-23 English
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024
Director's Dealing Classification · 1% confidence The document text consists of detailed tables reporting daily transactions of shares by an issuer (IPSEN) through a broker (Natixis) on various markets (XPAR, CEUX). Key indicators include transaction dates, volume, price, and explicit mention of 'Purpose of the buyback' being 'MAR Regulation Art 5 §2'. This structure is characteristic of mandatory regulatory filings disclosing insider or company share transactions, specifically share repurchases or dealings by directors/executives. This aligns directly with the definition for Director's Dealing (DIRS), which covers personal share transactions by directors and executives, and often includes mandatory disclosures related to share buybacks under market abuse regulations (MAR). Although the purpose mentions buyback, the format strongly suggests a mandatory disclosure of transactions by an insider or related party, making DIRS the most appropriate fit among the provided options, as it covers executive/director transactions, which often overlap with mandatory buyback disclosures.
2024-07-16 English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 28 - 2024
Transaction in Own Shares Classification · 1% confidence The document text consists of detailed tables showing transactions involving the issuer 'IPSEN' and a 'PSI' (likely a broker or intermediary like Natixis) over several days in July 2024. The tables detail the volume, price, and market of transactions. The second table explicitly mentions 'Objectif du rachat' (Purpose of the repurchase) as 'MAR Regulation Art 5 §2', which strongly indicates transactions related to share buybacks or treasury shares. This aligns directly with the definition of 'Transaction in Own Shares' (POS), which covers company buying back or selling its own shares.
2024-07-16 French
Ipsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Monthly information relative to the total number of voting rights and shares composing the share capital' and explicitly references compliance with French Commercial Code and AMF regulations. It provides a table detailing the total number of shares and the total number of voting rights as of a specific date (30 June 2024). This type of regular disclosure concerning the composition of share capital and voting rights is a specific regulatory filing requirement, often related to changes in ownership structure or capital base, but it is not a general earnings release, annual report, or director's dealing. It most closely aligns with notifications regarding share capital structure or major shareholding changes. Since it details the total number of shares and voting rights, it is a specific disclosure related to the capital structure. While 'MRQ' (Major Shareholding Notification) deals with crossing thresholds, this document provides the absolute count of shares and voting rights, which is a fundamental capital structure disclosure. Given the options, this specific monthly disclosure about the total number of shares and voting rights is best categorized as a regulatory filing that doesn't fit the other specific categories like DIV, DIRS, or DEF 14A. However, if we look closely at the definitions, 'MRQ' is for 'Notification of changes in significant share ownership levels (crossing thresholds)'. This document provides the base figures used for such calculations. Since it is a mandatory, periodic disclosure about the capital base, and it doesn't fit perfectly elsewhere, 'RNS' (Regulatory Filings - general fallback) is a possibility. But, because it is a direct report on the composition of the share capital and voting rights, which is often required alongside major shareholding reports, and given the highly specific nature of the other codes, this type of mandatory monthly capital structure update is often grouped with filings related to share ownership changes. Since it is not a general announcement of a report (RPA), and it is a specific regulatory disclosure, I will check if any other code fits better. 'SHA' is for 'Share Issue/Capital Change', which is too broad. 'MRQ' is for crossing thresholds. Given the content is a mandatory disclosure about the total share capital and voting rights, which is a core component of regulatory reporting not covered by the other specific codes (like ER, 10-K, DIV), 'RNS' (Regulatory Filings) serves as the most appropriate general regulatory disclosure category when a more specific one is unavailable or a poor fit. However, in many jurisdictions, these monthly voting rights disclosures are considered part of the broader capital structure reporting. Since it is a mandatory disclosure about the total number of shares and voting rights, it is a specific regulatory filing. I will classify it as RNS as the best fit among the provided options for a mandatory, non-financial, non-management disclosure.
2024-07-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.